DICOM structured reporting and cancer clinical trials results.
The use of biomarkers derived from radiological images as surrogate end-points in therapeutic cancer clinical trials is well established. DICOM is the ubiquitous standard for the interchange of images for both clinical use as well as research. It also has capabilities for the exchange of image-related information, including categorical and quantitative information derived from images. The use of DICOM Structured Reporting for the encoding and interchange of clinical trial results in a standard manner is reviewed.
Clunie
David A
DA
RadPharm, Princeton, NJ 08540, USA. dclunie@dclunie.com